Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Enhertu (fam-trastuzumab deruxtecan-nxki)
i
Other names:
T DXd, WHO10516, WHO-10516, DS 8201, DS8201a, DS 8201a, TDXd, DS-8201, DS-8201a, WHO 10516, T-DXd, DS8201
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(90)
News
Trials
Company:
AstraZeneca, Daiichi Sankyo
Drug class:
Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
Related drugs:
‹
irinotecan (48)
U3-1402 (28)
sacituzumab govitecan-hziy (17)
topotecan (16)
SHR-A1811 (15)
DS-1062a (11)
DM001 (6)
DS-7300 (5)
AZD8205 (5)
AMB302 (4)
BNT323 (4)
DB-1310 (4)
DM002 (4)
BL-M07D1 (3)
DS-6157 (3)
HRA00129-C004 (3)
nanoliposomal irinotecan (3)
PLX038 (3)
MK-2870 (3)
ABBV-400 (3)
CUSP06 (2)
DAN-222 (2)
DM005 (2)
PRO1102 (2)
SSH20 (2)
IMMU-130 (2)
AZD9592 (2)
AMT-562 (1)
AZD5335 (1)
BAT8008 (1)
BL-M02D1 (1)
BNT324 (1)
camptothecin nanosomal (1)
DAN-311 (1)
ELU001 (1)
ESG401 (1)
HMBD-501 (1)
IBI-343 (1)
IMMU-140 (1)
IT-141 (1)
OBI-992 (1)
PF-08046044 (1)
SGN-CD30C (1)
STRO-003 (1)
ZW191 (1)
ZW220 (1)
ZW251 (1)
BL-B01D1 (1)
PRO1184 (1)
ABBV-706 (0)
BAT8007 (0)
BAT8010 (0)
BL-M11D1 (0)
BNT326 (0)
CEB-01 (0)
belotecan (0)
DS-3939 (0)
FZ-AD004 (0)
GEN1160 (0)
GSK5733584 (0)
GSK5764227 (0)
HA-irinotecan (0)
HLX43 (0)
IBI-354 (0)
ICAM‑1 ADC (0)
JSKN003 (0)
LMP744 (0)
LY4170156 (0)
lentinan (0)
TLC388 (0)
M9140 (0)
MHB036C (0)
MHB088C (0)
NK012 (0)
etirinotecan pegol (0)
SHR-A1912 (0)
SHR-A1921 (0)
SHR-A2009 (0)
SKB315 (0)
TQB2102 (0)
TQB2103 (0)
VIP236 (0)
YL201 (0)
CBX-12 (0)
EP0057 (0)
LMP400 (0)
HR070803 (0)
irinotecan liposomal (0)
LY01616 (0)
FF-10850 (0)
PEN-866 (0)
DS-6000 (0)
simmitecan (0)
topotecan episcleral (0)
ado-trastuzumab emtansine (97)
disitamab vedotin (27)
JNJ-0683 (9)
trastuzumab duocarmazine (6)
A166 (6)
MM-302 (4)
PF-06804103 (4)
SBT6050 (4)
XMT-1522 (3)
IKS014 (3)
MRG002 (3)
ZW49 (3)
BB-1701 (2)
ORM-5029 (2)
XMT-2056 (2)
DP303c (2)
ADC2122 (1)
ALT-P7 (1)
BAT8001 (1)
DHES0815A (1)
GQ1001 (1)
MEDI4276 (1)
MF-TTZ-MMAE (1)
MYX2449 (1)
TAA013 (1)
(1)
YH012 (1)
BT2111 (1)
ADCT-502 (0)
DX126-262 (0)
GQ1007 (0)
SHR-4602 (0)
(0)
BI-CON-02 (0)
irinotecan (48)
U3-1402 (28)
sacituzumab govitecan-hziy (17)
topotecan (16)
SHR-A1811 (15)
DS-1062a (11)
DM001 (6)
DS-7300 (5)
AZD8205 (5)
AMB302 (4)
BNT323 (4)
DB-1310 (4)
DM002 (4)
BL-M07D1 (3)
DS-6157 (3)
HRA00129-C004 (3)
nanoliposomal irinotecan (3)
PLX038 (3)
MK-2870 (3)
ABBV-400 (3)
CUSP06 (2)
DAN-222 (2)
DM005 (2)
PRO1102 (2)
SSH20 (2)
IMMU-130 (2)
AZD9592 (2)
AMT-562 (1)
AZD5335 (1)
BAT8008 (1)
BL-M02D1 (1)
BNT324 (1)
camptothecin nanosomal (1)
DAN-311 (1)
ELU001 (1)
ESG401 (1)
HMBD-501 (1)
IBI-343 (1)
IMMU-140 (1)
IT-141 (1)
OBI-992 (1)
PF-08046044 (1)
SGN-CD30C (1)
STRO-003 (1)
ZW191 (1)
ZW220 (1)
ZW251 (1)
BL-B01D1 (1)
PRO1184 (1)
ABBV-706 (0)
BAT8007 (0)
BAT8010 (0)
BL-M11D1 (0)
BNT326 (0)
CEB-01 (0)
belotecan (0)
DS-3939 (0)
FZ-AD004 (0)
GEN1160 (0)
GSK5733584 (0)
GSK5764227 (0)
HA-irinotecan (0)
HLX43 (0)
IBI-354 (0)
ICAM‑1 ADC (0)
JSKN003 (0)
LMP744 (0)
LY4170156 (0)
lentinan (0)
TLC388 (0)
M9140 (0)
MHB036C (0)
MHB088C (0)
NK012 (0)
etirinotecan pegol (0)
SHR-A1912 (0)
SHR-A1921 (0)
SHR-A2009 (0)
SKB315 (0)
TQB2102 (0)
TQB2103 (0)
VIP236 (0)
YL201 (0)
CBX-12 (0)
EP0057 (0)
LMP400 (0)
HR070803 (0)
irinotecan liposomal (0)
LY01616 (0)
FF-10850 (0)
PEN-866 (0)
DS-6000 (0)
simmitecan (0)
topotecan episcleral (0)
ado-trastuzumab emtansine (97)
disitamab vedotin (27)
JNJ-0683 (9)
trastuzumab duocarmazine (6)
A166 (6)
MM-302 (4)
PF-06804103 (4)
SBT6050 (4)
XMT-1522 (3)
IKS014 (3)
MRG002 (3)
ZW49 (3)
BB-1701 (2)
ORM-5029 (2)
XMT-2056 (2)
DP303c (2)
ADC2122 (1)
ALT-P7 (1)
BAT8001 (1)
DHES0815A (1)
GQ1001 (1)
MEDI4276 (1)
MF-TTZ-MMAE (1)
MYX2449 (1)
TAA013 (1)
(1)
YH012 (1)
BT2111 (1)
ADCT-502 (0)
DX126-262 (0)
GQ1007 (0)
SHR-4602 (0)
(0)
BI-CON-02 (0)
›
Associations
(90)
News
Trials
VERI cancer hierarchy
Reset Filters
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 expression
Solid Tumor
HER-2 expression
Solid Tumor
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 amplification
Colorectal Cancer
HER-2 amplification
Colorectal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
HER-2 overexpression
Esophageal Adenocarcinoma
HER-2 overexpression
Esophageal Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
HER-2 amplification
Rectal Cancer
HER-2 amplification
Rectal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
HER-2 overexpression
Gastric Adenocarcinoma
HER-2 overexpression
Gastric Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
HER-2 positive
Salivary Gland Cancer
HER-2 positive
Salivary Gland Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
No biomarker
Rectal Cancer
No biomarker
Rectal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
HER-2 amplification + RAS wild-type + BRAF wild-type
Rectal Cancer
HER-2 amplification + RAS wild-type + BRAF wild-type
Rectal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
HER-2 amplification + RAS wild-type + BRAF wild-type
Colon Cancer
HER-2 amplification + RAS wild-type + BRAF wild-type
Colon Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
HER-2 positive
Cervical Cancer
HER-2 positive
Cervical Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
HER-2 positive
Endometrial Cancer
HER-2 positive
Endometrial Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
HER-2 expression
Colorectal Cancer
HER-2 expression
Colorectal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
B
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
B
HER-2 underexpression
Hormone Receptor Positive Breast Cancer
HER-2 underexpression
Hormone Receptor Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
B
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
B
PD-L1 underexpression
HER2 Positive Breast Cancer
PD-L1 underexpression
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
B
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
B
HER-2 underexpression + ER underexpression
Breast Cancer
HER-2 underexpression + ER underexpression
Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
B
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
B
HER-2 underexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 underexpression
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 expression
Endometrial Cancer
HER-2 expression
Endometrial Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 expression
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 expression
Salivary Gland Cancer
HER-2 expression
Salivary Gland Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 positive
Colorectal Cancer
HER-2 positive
Colorectal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 mutation
Colorectal Cancer
HER-2 mutation
Colorectal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 mutation
Breast Cancer
HER-2 mutation
Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 underexpression
Gastric Cancer
HER-2 underexpression
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login